SCP
ALNY icon

Sivia Capital Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sivia Capital Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$393K Buy
+1,305
New +$394K 0.05% 405
2026
Q1 		– Sell
-1,997
Closed -$794K – 468
2025
Q4 		$794K Buy
1,997
+901
+82% +$399K 0.16% 164
2025
Q3 		$500K Buy
+1,096
New +$446K 0.14% 170

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sivia Capital Partners's ALNY Position: Q2 2026 in Review

Sivia Capital Partners opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 1,305 shares worth $393K. The stake represents 0.05% of the portfolio and ranks #405 among its holdings. This is a return to the name: Sivia Capital Partners previously reported a position in ALNY as recently as Q4 2025.

Sivia Capital Partners first reported a position in ALNY in Q3 2025 and has held it in 3 quarters since. The position peaked at $794K in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Sivia Capital Partners held 1,305 shares of Alnylam Pharmaceuticals worth $393K as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Sivia Capital Partners position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.05% of Sivia Capital Partners's portfolio in Q2 2026, its #405 holding.
  • Sivia Capital Partners first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Sivia Capital Partners's Alnylam Pharmaceuticals position peaked at $794K in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Sivia Capital Partners's 13F filing for Q2 2026, filed 23 Jul 2026.